Insider trade

CEO sold ~$397K of GILD shares in the open market

Traded Apr 28, 2026 · Filed Apr 29, 2026

Gilead SciencesGILD

~$397K
Reported value · 3,050 sh @ $130.0111: 633K
Holds after · shares reported: +14.1%
stock since the trade · S&P 500 +7.3%, $129.26 → $147.50 on Oct 1

Why it stands out

The boss of Gilead Sciences sold $397K of Gilead Sciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Apr 28, 2026
Reporting period: Not applicable
Filed with the SEC: Apr 29, 2026

CEO$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$396,534

Shares × reported transaction price

Timing vs results

77 days after results of Feb 10, 2026, 9 days before results of May 7, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $129.26 on Apr 28, 2026, 33% above its 52-week low and 17% below its high, after an 11% drop over the previous 30 trading days

52-week range $96.91 (May 9, 2025) to $155.80 (Feb 11, 2026), 55% of the way up, from 251 adjusted closes. 30 trading days earlier: $145.21 on Mar 16, 2026. Describes the past only, not a forecast

Layoff notice nearby

A WARN layoff notice covering 108 workers was filed in California on April 30, 2026.

From the official state WARN list, 2 days after the trade; 1 more notice by the company within 60 days. Shown for timing only; the two filings are separate

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Hepcludex on May 22, 2026, 24 days after this trade.

Biologic approved. Active ingredient: Bulevirtide-Gmod. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+2.5%	+1.8%	+0.7%
30 days	+0.2%	+5.5%	-5.3%
90 days	+1.4%	+1.5%	-0.1%

Past results only. Not a forecast.

Source receipt

Record ID: 0001638643-26-000020
Filed / recorded: Apr 29, 2026, 9:53 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: GILEAD SCIENCES, INC.
Issuer CIK: 882095
Ticker: GILD
Reporting person: Daniel Patrick O'day
Relationship: Director, Officer
Officer title: Chairman & CEO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Apr 28, 2026
Transaction code: S
Shares / units: 3,050
Price per share: $130.0111
Acquired / disposed: Disposed (D)
Shares owned after: 632,567
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
Sale prices for the transactions reported range from $129.42 to $130.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.